Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

Purpose Despite impressive response rates following adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, improvement is needed to increase the efficacy and broaden the applicability of this treatment. We evaluated the use of vemurafenib, a small...

Full description

Bibliographic Details
Main Authors: Marco Donia, Rikke Andersen, Troels Holz Borch, Per Kongsted, Özcan Met, Julie Westerlin Kjeldsen, Morten Nielsen, Magnus Pedersen, Martin Lauss, Göran Jönsson, Inge Marie Svane, Katja Harbst, Aynal Haque Rana, Evelina Martinenaite, Anders Handrup Kverneland, Lisbet Rosenkrantz Hölmich, Helle Hendel
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002703.full

Internet

https://jitc.bmj.com/content/9/7/e002703.full

Similar Items